atrial fibrillation

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathMajor bleeding

antiarrythmic drugs  

not classified  
SMART, 2002     aprindineplaceboLow risk of bias negative
AFIB, 1997     bidisomideplacebonegative101%
P-OM3 (Kowey), 2010   n-3 PUFAplaceboLow risk of bias negative
Okishige, 2000     pilsicainideplacebosuggesting∞%
RACE II, 2010    NCTlenient rate controlstrict rate controlRisk of bias negative46%
amiodarone  
Channer, 2004     amiodaroneplaceboLow risk of bias suggesting
GEFACA, 2001   amiodaroneplaceboLow risk of bias suggesting
Kochiadakis (amiodarone vs placebo), 2000       amiodaroneplacebosuggesting
SAFE-T (amiodarone vs placebo), 2005       amiodaroneplaceboLow risk of bias suggesting114%
AFFIRM Substudy (amiodarone vs class I drugs), 2003     amiodaroneclass I drugsRisk of bias suggesting-58%
AFFIRM Substudy (sotalol vs class I drugs), 2003     amiodaroneclass I drugs -
Villani, 1992   amiodaronedisopyramidesuggesting
Kochiadakis a, 2004       amiodaronepropafenonenegative
Vitolo, 1981   amiodaronequinidinesuggesting
AFFIRM Substudy (amiodarone vs sotalol), 2003     amiodaronesotalolsuggesting-40%
Kochiadakis (amiodarone vs sotalol), 2000     amiodaronesotalol -
SAFE-T (amiodarone vs sotalol), 2005     amiodaronesotalolLow risk of bias -
Azimilide  
ASAP, 2003             AzimilideplaceboLow risk of bias negative 23%
disopyramide  
Karlson, 1998     disopyramideplacebonegative∞%
Lloyd (Disopyramide vs placebo), 1984   disopyramideplaceboLow risk of bias negative
PRODIS, 1996   disopyramidepropafenoneLow risk of bias negative∞%
Lloyd (Disopyramide vs quinidine), 1984   disopyramidequinidineLow risk of bias -
dofetilide  
DIAMOND, 2001       dofetilideplaceboLow risk of bias suggesting-1%
SAFIRE-D, 2000     dofetilideplaceboLow risk of bias suggesting-25%
dronedarone  
EURIDIS, 2007      NCTdronedaroneplaceboLow risk of bias suggesting
ADONIS, 2007    NCTdronedaroneplaceboLow risk of bias suggesting
DAFNE, 2003     dronedaroneplaceboLow risk of bias suggesting∞%
EURIDIS ADONIS (pooled analysis), 2009   dronedaroneplaceboLow risk of bias negative32%
ATHENA, 2009      NCTdronedaroneplaceboLow risk of bias suggesting -16%
PALLAS, 2011        NCTdronedaroneplaceboLow risk of bias negative 128%
ERATO, 2008   dronedaroneplaceboLow risk of bias negative∞%
DIONISOS, 2007      NCTdronedaroneamiodaroneLow risk of bias suggesting -59%
flecainide  
Van Gelder, 1989   flecainideno treatmentnegative
Carunchio (flecainide vs placebo), 1995   flecainideplacebosuggesting
Steinbeck (flecainide vs digoxin), 1988   flecainidedigoxinsuggesting
Aliot, 1996     flecainidepropafenonesuggesting-100%
Naccarelli, 1996     flecainidequinidineLow risk of bias negative
metoprolol  
Kuhlkamp, 2000     metoprololplacebonegative ∞%
propafenone  
Bellandi (propafenone vs placebo), 2001     propafenoneplaceboLow risk of bias suggesting
Dogan, 2004   propafenoneplacebosuggesting-100%
Kochiadakis b (propafenone vs placebo), 2004       propafenoneplacebosuggesting
RAFT, 2003     propafenoneplaceboLow risk of bias suggesting
Stroobandt, 1997     propafenoneplaceboLow risk of bias negative-100%
FAPIS, 1996       propafenoneflecainidenegative
Richiardi, 1992   propafenonequinidinenegative -100%
Reimold, 1993     propafenonesotalolnegative∞%
quinidine  
Hillestad, 1971     quinidineno treatmentnegative∞%
Sodermark, 1975     quinidineno treatmentsuggesting 105%
Lloyd (quinidine vs placebo), 1984   quinidineplaceboLow risk of bias negative∞%
PAFAC (quinidine vs placebo), 2004       quinidineplaceboLow risk of bias suggesting5%
SOPAT (quinidine vs placebo), 2004       quinidineplaceboLow risk of bias suggesting∞%
Byrne Quinn, 1979     quinidineplaceboLow risk of bias suggesting∞%
Steinbeck (quinidine vs digoxin), 1988   quinidinedigoxinnegative
Lloyd (quinidine vs disopyramide), 1984   quinidinedisopyramideLow risk of bias -
Steinbeck (quinidine vs flecainide), 1988   quinidineflecainide -
Hohnloser, 1995     quinidinesotalolnegative
Juul-Moller, 1990   quinidinesotalolnegative 15%
Kalusche, 1994   quinidinesotalolnegative∞%
SOCESP, 1999     quinidinesotalolnegative-100%
PAFAC (quinidine vs sotalol), 2004     quinidinesotalolLow risk of bias -
SOPAT (quinidine vs sotalol), 2004   quinidinesotalolLow risk of bias -
sotalol  
Benditt, 1999     sotalolplaceboLow risk of bias negative
Singh, 1991   sotalolplaceboLow risk of bias suggesting
Bellandi (sotalol vs placebo), 2001   sotalolplaceboLow risk of bias suggesting
Carunchio (sotalol vs placebo), 1995   sotalolplacebosuggesting
Kochiadakis (sotalol vs placebo), 2000   sotalolplacebo -
Kochiadakis b (sotalol vs placebo), 2004     sotalolplacebosuggesting
PAFAC (sotalol vs placebo), 2004     sotalolplaceboLow risk of bias suggesting49%
SAFE-T (sotalol vs placebo), 2005       sotalolplaceboLow risk of bias suggesting153%
SOPAT (sotalol vs placebo), 2004   sotalolplaceboLow risk of bias negative∞%
Plewan, 2001     sotalolbisoprololnegative
Carunchio (sotalol vs flecianide), 1995   sotalolflecainide -
Kochiadakis b (sotalol vs propafenome), 2004   sotalolpropafenone -

antithrombotics  

not classified  
Japanese AF Trial, 2006     aspirincontrol -
EAFT, 1993   oral anticoagulantplacebosuggesting
ENGAGE-AF TIMI 48 Low dose, 2013    NCTedoxaban low dosewarfarin standard doseLow risk of bias suggesting -13%-53%
phase 2 AZD0837    NCTAZD0837aspirinExploratory -
NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004     triflusal+coumadin medium dosecoumadin standard doseRisk of bias suggesting
NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004     triflusal+coumadin medium dosetriflusalLow risk of bias suggesting
SIFA, 1997      NCTIndobufenwarfarinsuggesting-100%
Lip (phase 2 AZD0837), 2009    NCTAZD0837warfarin standard doseExploratory -
phase 2 YM150    NCTYM150warfarin standard doseExploratory -
apixaban  
AVERROES, 2011        NCTapixabanaspirinineligible for VKALow risk of bias suggesting -21%14%
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive-11%-30%
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -
aspirin  
LASAF(aspirin vs no treatment), 1999     aspirincontrol -
AFASAK (aspirin vs placebo), 1989   aspirinplaceboLow risk of bias negative∞%
SPAF (aspirin,warfarin ineligible arm), 1991   aspirinplaceboineligible for VKALow risk of bias negative
SPAF (aspirin , warfarin eligible arm), 1991   aspirinplaceboLow risk of bias suggesting
EAFT, 1993   aspirinplaceboLow risk of bias negative
FFAACS , 2001     aspirinplacebo (on top fluidione)Low risk of bias negative
PATAF (vs coumadin low dose), 1999     aspirincoumadin low doseRisk of bias negative
PATAF (vs coumadin standard dose), 1999     aspirincoumadin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin low dose), 1998     aspirinwarfarin low doseRisk of bias negative131%65%
SPAF II (aspirin vs warfarin standard dose, age<75), 1994   aspirinwarfarin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin standard dose), 1998     aspirinwarfarin standard doseRisk of bias negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994   aspirinwarfarin standard doseRisk of bias negative
AFASAK (aspirin vs warfarin standard dose), 1989   aspirinwarfarin standard doseRisk of bias negative
clopidogrel  
ACTIVE W, 2006    NCTaspirin + clopidogrelanticoagulantRisk of bias suggesting 2%10%
ACTIVE A, 2009      NCTaspirin + clopidogrelaspirinLow risk of bias suggesting -2%57%
coumadin  
PATAF (coumadin low dose vs coumadin standard dose), 1999     coumadin low dosecoumadin standard doseRisk of bias negative
dabigatran  
RE-LY 110mg (2nd prevention subgroup) , 2010   dabigatran 100mgwarfarinExploratory suggesting
RE-LY 150mg (2nd prevention subgroup)   dabigatran 150mgwarfarinExploratory suggesting
phase 2 dabigatran    NCTdabigatranwarfarin standard doseExploratory -
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting-9%-20%
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting -12%-7%
edoxaban  
Weitz (edoxaban phase 2)    NCTedoxabanwarfarin standard doseExploratory -
phase 2 edoxaban    NCTedoxabanwarfarin standard doseExploratory -
ENGAGE-AF TIMI 48 High dose, 2013    NCTedoxaban high dosewarfarin standard doseLow risk of bias suggesting -8%-20%
idraparinux  
AMADEUS, 2008      NCTidraparinuxwarfarin standard doseRisk of bias negative 12%167%
rivaroxaban  
ROCKET (2nd prevention subgroup) , 2011   rivaroxabanwarfarinLow risk of bias negative
ROCKET-AF, 2010        NCTrivaroxabanwarfarin standard doseLow risk of bias suggesting -8%4%
triflusal  
NASPEAF (triflusal vs coumadin standard dose)), 2004     triflusalcoumadin standard doseRisk of bias negative
warfarin  
BAATAF (warfarin vs no treatment), 1990    NCTwarfarin low dosecontrolRisk of bias suggesting -58%96%
SAFT(warfarin low dose + aspirin vs no treatment), 2003     warfarin low dose + aspirincontrolRisk of bias negative -14%
AFASAK (warfarin standard dose vs control), 1989   warfarin standard dosecontrolRisk of bias suggesting∞%
SPAF (warfarin standard dose), 1991   warfarin standard dosecontrolRisk of bias suggesting-25%0%
SPINAF (warfarin vs placebo), 1992   warfarin low doseplaceboLow risk of bias negative
CAFA, 1991   warfarin standard doseplaceboLow risk of bias negative411%
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998     warfarin + aspirinwarfarin standard doseRisk of bias negative
SPAF III, 1996   warfarin + aspirinwarfarin standard doseRisk of bias remark
AFASAK II (warfarin low dose vs warfarin standard dose), 1998     warfarin low dosewarfarin standard doseRisk of bias negative
MWNAF, 1998     warfarin low dosewarfarin standard doseRisk of bias negative
ximelagatran  
SPORTIF II (ximelagatran vs warfarin standard dose), 2002     ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003     ximelagatranwarfarin standard doseRisk of bias suggesting-1%-29%
SPORTIF V, 2005       ximelagatranwarfarin standard doseLow risk of bias suggesting -6%-25%

catheter ablation  

catheter ablation  
A4 (Jais), 2008      NCTcatheter ablationcontrolRisk of bias suggesting-100%
Wazni , 2005     catheter ablationcontrolRisk of bias suggesting
APAF (Pappone), 2006     catheter ablationcontrolRisk of bias suggesting
CAFCOAF (Stabile), 2006     catheter ablationcontrolRisk of bias suggesting-49%
Krittayaphong, 2003   catheter ablationcontrolRisk of bias suggesting
ThermoCool AF, 2008      NCTcatheter ablationcontrolRisk of bias suggesting∞%
Oral, 2006     catheter ablationcontrolLow risk of bias suggesting∞%
Forleo, 2009     catheter ablationcontrolRisk of bias suggesting
Lakkireddy, 2006   catheter ablationcontrolRisk of bias -
CABANA, 2018    NCTcatheter ablationcontrolRisk of bias suggesting-15%
STOP-AF, 2010      NCTcatheter ablationcontrolRisk of bias -

direct antithrombins  

dabigatran  
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting-9%-20%
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting -12%-7%
ximelagatran  
SPORTIF II (ximelagatran vs warfarin standard dose), 2002     ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003     ximelagatranwarfarin standard doseRisk of bias suggesting-1%-29%
SPORTIF V, 2005       ximelagatranwarfarin standard doseLow risk of bias suggesting -6%-25%

direct factor Xa inhibitors  

not classified  
ENGAGE-AF TIMI 48 Low dose, 2013    NCTedoxaban low dosewarfarin standard doseLow risk of bias suggesting -13%-53%
phase 2 YM150    NCTYM150warfarin standard doseExploratory -
apixaban  
AVERROES, 2011        NCTapixabanaspirinineligible for VKALow risk of bias suggesting -21%14%
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive-11%-30%
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -
edoxaban  
Weitz (edoxaban phase 2)    NCTedoxabanwarfarin standard doseExploratory -
phase 2 edoxaban    NCTedoxabanwarfarin standard doseExploratory -
ENGAGE-AF TIMI 48 High dose, 2013    NCTedoxaban high dosewarfarin standard doseLow risk of bias suggesting -8%-20%
rivaroxaban  
ROCKET-AF, 2010        NCTrivaroxabanwarfarin standard doseLow risk of bias suggesting -8%4%

direct oral anticoagulant (DAO)  

not classified  
ENGAGE-AF TIMI 48 Low dose, 2013    NCTedoxaban low dosewarfarin standard doseLow risk of bias suggesting -13%-53%
phase 2 AZD0837    NCTAZD0837aspirinExploratory -
Lip (phase 2 AZD0837), 2009    NCTAZD0837warfarin standard doseExploratory -
phase 2 YM150    NCTYM150warfarin standard doseExploratory -
apixaban  
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive-11%-30%
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -
dabigatran  
phase 2 dabigatran    NCTdabigatranwarfarin standard doseExploratory -
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting-9%-20%
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting -12%-7%
edoxaban  
Weitz (edoxaban phase 2)    NCTedoxabanwarfarin standard doseExploratory -
phase 2 edoxaban    NCTedoxabanwarfarin standard doseExploratory -
ENGAGE-AF TIMI 48 High dose, 2013    NCTedoxaban high dosewarfarin standard doseLow risk of bias suggesting -8%-20%
idraparinux  
AMADEUS, 2008      NCTidraparinuxwarfarin standard doseRisk of bias negative 12%167%
rivaroxaban  
ROCKET-AF, 2010        NCTrivaroxabanwarfarin standard doseLow risk of bias suggesting -8%4%
ximelagatran  
SPORTIF II (ximelagatran vs warfarin standard dose), 2002     ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003     ximelagatranwarfarin standard doseRisk of bias suggesting-1%-29%
SPORTIF V, 2005       ximelagatranwarfarin standard doseLow risk of bias suggesting -6%-25%

embolic protection  

not classified  
PROTECT-AF    NCTWatchmanwarfarinnegative

prevention  

not classified  
TRACE (AF ancillary study), 1999     trandolaprilplacebosuggesting
atorvastatin  
Ozaydin, 2006     atorvastatincontrolExploratory suggesting
Almroth, 2009     atorvastatin placeboLow risk of bias suggesting
MIRACL (sub-group) (Schwartz), 2004   atorvastatinplaceboLow risk of bias suggesting
Dernellis, 2006     atorvastatinplaceboExploratory suggesting
ARMYDA-3 (AF ancillary study), 2006     atorvastatinplacebosuggesting
Chello, 2006     atorvastatinplaceboLow risk of bias negative
MIRACL (AF ancillary study), 2001     atorvastatinplaceboLow risk of bias negative
candesartan  
CAPRAF (Tveit), 2007      NCTcandesartanplaceboLow risk of bias -
CHARM (AF ancillary study), 2005     candesartanplacebosuggesting
enalapril  
Ueng, 2003     enalaprilcontrolsuggesting
SOLVD (AF ancillary study), 2003     enalaprilplacebosuggesting
gemfibrozil  
VA HIT (AF ancillary study), 1999       gemfibrozilplaceboLow risk of bias negative
irbesartan  
Madrid, 2002     irbesartancontrolsuggesting
ACTIVE I, 2009    NCTirbesartanplaceboLow risk of bias suggesting
lisinopril  
Van den Burg, 1995   lisinoprilplaceboLow risk of bias negative
GISSI-3 (AF ancillary study), 2003     lisinoprilplacebonegative
losartan  
LIFE (AF ancillary study), 2005     losartanatenololsuggesting
pravastatin  
Tveit, 2004     pravastatincontrolExploratory negative
rosuvastatin  
GISSI HF (subgroup and ancillary study), 2009    NCTrosuvastatin placeboLow risk of bias negative
valsartan  
GISSI-AF (Disertori), 2009      NCTvalsartanplaceboLow risk of bias negative
Val-HeFT (AF ancillary study), 2003   valsartanplacebosuggesting

rate control  

not classified  
Hot cafe (rate vs rythm control), 2004   rate controlelectrical cardioversionnegative -66%∞%
RACE (rate vs rythm control), 2002   rate controlelectrical cardioversionnegative 15%39%
STAF (rate vs rythm control), 2003     rate controlelectrical cardioversionnegative 100%-27%
AFFIRM (rate vs rythm control), 2002      NCTrate controlpharmacological cardioversionsuggesting-13%12%
PIAF (rate vs rythm control), 2000     rate controlpharmacological cardioversionsuggesting2%-100%
AF-CHF (rate vs rythm control), 2002    NCTrate controlpharmacological cardioversion -
RACE II, 2010    NCTlenient rate controlstrict rate controlRisk of bias negative46%

rythm control  

not classified  
P-OM3 (Kowey), 2010   n-3 PUFAplaceboLow risk of bias negative
Hot cafe, 2004     electrical cardioversionrate controlRisk of bias suggesting191%-100%
RACE, 2002       electrical cardioversionrate controlRisk of bias suggesting-13%-28%
STAF, 2003     electrical cardioversionrate controlRisk of bias suggesting-50%38%
AFFIRM, 2002      NCTpharmacological cardioversionrate controlRisk of bias negative 14%-11%
PIAF, 2000     pharmacological cardioversionrate controlRisk of bias negative -2%∞%
AF-CHF, 2002    NCTpharmacological cardioversionrate controlRisk of bias -